Natixis Buys Shares of 11,376 DaVita Inc. (NYSE:DVA)

Natixis purchased a new position in shares of DaVita Inc. (NYSE:DVA - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 11,376 shares of the company's stock, valued at approximately $1,701,000.

Several other institutional investors and hedge funds also recently modified their holdings of DVA. Norinchukin Bank The lifted its holdings in DaVita by 9.4% in the fourth quarter. Norinchukin Bank The now owns 2,113 shares of the company's stock worth $316,000 after purchasing an additional 182 shares during the period. Ossiam lifted its stake in shares of DaVita by 71.5% in the 4th quarter. Ossiam now owns 8,105 shares of the company's stock worth $1,212,000 after acquiring an additional 3,378 shares during the period. BI Asset Management Fondsmaeglerselskab A S boosted its holdings in shares of DaVita by 153.0% in the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 131,873 shares of the company's stock valued at $19,722,000 after acquiring an additional 79,742 shares in the last quarter. Epoch Investment Partners Inc. acquired a new position in shares of DaVita during the fourth quarter valued at approximately $55,100,000. Finally, Freedom Investment Management Inc. raised its holdings in DaVita by 3.6% during the fourth quarter. Freedom Investment Management Inc. now owns 1,790 shares of the company's stock worth $268,000 after purchasing an additional 62 shares in the last quarter. Institutional investors own 90.12% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Cowen restated a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research note on Friday, February 21st. Barclays raised their target price on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Tuesday, February 18th. Finally, StockNews.com raised DaVita from a "hold" rating to a "buy" rating in a report on Friday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $166.33.

DaVita Trading Down 0.1 %

Shares of DVA stock traded down $0.08 during trading hours on Monday, reaching $139.49. 133,826 shares of the stock traded hands, compared to its average volume of 838,928. The business has a fifty day moving average price of $146.50 and a 200 day moving average price of $155.24. DaVita Inc. has a 1-year low of $131.27 and a 1-year high of $179.60. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. The firm has a market capitalization of $11.16 billion, a PE ratio of 13.02, a PEG ratio of 1.07 and a beta of 1.04.

DaVita (NYSE:DVA - Get Free Report) last issued its earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, equities research analysts forecast that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.